Open Repeat Immunoadsorption Post Covid ME/CFS

RedFox · Dec 16, 2022

Repeat Immunoadsorption Post Covid ME/CFS
https://clinicaltrials.gov/ct2/show/NCT05629988

From Dr. Carmen Scheibenbogen's team at Charite University.
Their summary:

The evidence for an autoimmune etiology in postinfectious myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is growing. The investigators observed in a not yet published study that in ME/CFS triggered by COVID, similar to ME/CFS after other infections, there is a close correlation of ß2 adrenergic receptor (ß2R) autoantibodies with symptom severity.

Immunoadsorption (IA) to remove autoantibodies has been used successfully in many autoantibody-mediated diseases. The investigators have already performed two proof of concept studies of IA in postinfectious ME/CFS with elevated ß2R antibodies, which resulted in improvement in most patients. This observational study aims to assess symptom outcome and functional ability in 20 patients with Post-COVID Syndrome (PCS) meeting ME/CFS diagnostic criteria with elevated ß2R antibodies undergoing antibody depletion by IA. The study will be conducted as a non-interventional observational study. IA with Miltenyi's TheraSorb® column in PCS will be performed in the approved use. Patients who have symptom improvement after the 1st IA will receive two additional IAs at 3 and 6 months, which will also be documented.

The results of this observational study will provide the basis for a randomized controlled clinical trial (RCT) combining IA with B-cell depletion therapy preferentially with Obinutuzumab.
Click to expand...

It's an observational study with no control group, so not rigorous. But after this study they want to do an RCT.

Log in or Sign up

Open Repeat Immunoadsorption Post Covid ME/CFS

RedFox Senior Member (Voting Rights)

Share This Page

Log in or Sign up

Open Repeat Immunoadsorption Post Covid ME/CFS

RedFox Senior Member (Voting Rights)

Share This Page

Useful Searches